Anti-interleukin 6 receptor antibody treatment in rheumatic disease
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
复制标题
DOI：
10.1136/ard.59.suppl_1.i21
复制
发表时间：
2000-11-01
影响因子：
27.4
通讯作者：
Yoshizaki, K
中科院分区：
文献类型：
--
作者：
Nishimoto, N;Kishimoto, T;Yoshizaki, K
白细胞介素6（IL 6）是一种具有广泛生物学活性的多效性细胞因子。IL 6转基因小鼠引起异常，如高γ-球蛋白血症、血小板增多、炎性细胞浸润到组织中、肾脏的系膜细胞增殖以及脾肿大和淋巴结病，这些都是通过体外显示的IL 6的生物学功能可预测的。在某些免疫炎症性疾病（例如Castleman病和类风湿性关节炎）患者中观察到IL 6持续过量产生，这些疾病通常与IL 6转基因小鼠的异常类似，强烈表明IL 6参与了人类疾病。因此，用抗IL 6受体（IL 6 R）抗体成功治疗免疫炎症疾病模型动物表明IL 6阻断剂可能应用于治疗人类IL 6相关免疫炎症疾病。本文综述了应用抗人IL 6受体人源化抗体MRA治疗Castleman病和RA的新策略。
Interleukin 6 (IL6) is a pleiotropic cytokine with a wide range of biological activities. IL6 transgene into mice gives rise to the abnormalities such as hyper-gamma -globulinaemia, thrombocytosis, infiltration of inflammatory cells into the tissues, mesangial cell proliferation of the kidney as well as splenomegaly and lymphadenopathy, which are predictable by the biological functions of IL6 shown in vitro. Continuous overproduction of IL6 is observed in patients with some immune-inflammatory diseases such as Castleman's disease and rheumatoid arthritis that are frequently associated with similar abnormalities to those of IL6 transgenic mice, strongly suggesting the involvement of IL6 in the human diseases. Successful treatment of the model animals for immune-inflammatory diseases with anti-IL6 receptor (IL6R) antibody thus indicates the possible application of IL6 blocking agents to treat the IL6 related immune-inflammatory diseases of humans. in this review, the new therapeutic strategy for Castleman's disease and RA using humanised antibody to human IL6 receptor, MRA, is discussed.